tiprankstipranks
Advertisement
Advertisement

DYN Stock Latest News

Dyne Therapeutics initiated with a Buy at TD Cowen
The FlyDyne Therapeutics initiated with a Buy at TD Cowen
16d ago
DYN
Joseph Thome Initiates Buy on Dyne Therapeutics, Citing Late-Stage Pipeline Strength and Multi-Billion-Dollar Peak Sales Potential
PremiumRatings
Joseph Thome Initiates Buy on Dyne Therapeutics, Citing Late-Stage Pipeline Strength and Multi-Billion-Dollar Peak Sales Potential
16d ago
DYN
Dyne Therapeutics Names Barry Greene Independent Board Director
PremiumCompany Announcements
Dyne Therapeutics Names Barry Greene Independent Board Director
19d ago
8K
DYN
Dyne Therapeutics Expands Hercules Debt Facility for Flexibility
PremiumCompany Announcements
Dyne Therapeutics Expands Hercules Debt Facility for Flexibility
25d ago
8K
DYN
Dyne Therapeutics Expands Share Authorization After Stockholder Approvals
PremiumCompany Announcements
Dyne Therapeutics Expands Share Authorization After Stockholder Approvals
1M ago
8K
DYN
Acting FDA head vows to block political interference, Endpoint News says
PremiumThe FlyActing FDA head vows to block political interference, Endpoint News says
1M ago
AZN
BMY
Analyst Reiterates Buy on Dyne Therapeutics, Maintains $44 Price Target on De-Risked Late-Stage Pipeline and Regulatory Momentum
Premium
Ratings
Analyst Reiterates Buy on Dyne Therapeutics, Maintains $44 Price Target on De-Risked Late-Stage Pipeline and Regulatory Momentum
1M ago
DYN
Dyne Therapeutics completes enrollment in ACHIEVE trial of zeleciment basivarsen
Premium
The Fly
Dyne Therapeutics completes enrollment in ACHIEVE trial of zeleciment basivarsen
1M ago
DYN
Dyne Fully Enrolls ACHIEVE Trial for DM1 Therapy
PremiumCompany Announcements
Dyne Fully Enrolls ACHIEVE Trial for DM1 Therapy
1M ago
8K
DYN
FDA issues draft guidance to help accelerated cell, gene therapies for patients
PremiumThe Fly
FDA issues draft guidance to help accelerated cell, gene therapies for patients
1M ago
AZN
BMY
Analyst Lifts Dyne Price Target to $47 on Strong DMD Execution, Phase 3 Progress and Expanding Exon-Skipping Pipeline
PremiumRatings
Analyst Lifts Dyne Price Target to $47 on Strong DMD Execution, Phase 3 Progress and Expanding Exon-Skipping Pipeline
2M ago
DYN
Dyne Therapeutics announces submission of BLA to U.S. FDA for z-rostudirsen
PremiumThe Fly
Dyne Therapeutics announces submission of BLA to U.S. FDA for z-rostudirsen
2M ago
DYN
Analyst Maintains Buy Rating on Dyne, Keeps $50 Price Target on Strength of FORZETTO Study Design and Z‑Rostudirsen Data
PremiumRatingsAnalyst Maintains Buy Rating on Dyne, Keeps $50 Price Target on Strength of FORZETTO Study Design and Z‑Rostudirsen Data
2M ago
DYN
Dyne Therapeutics initiates FORZETTO trial of zeleciment rostudirsen
Premium
The Fly
Dyne Therapeutics initiates FORZETTO trial of zeleciment rostudirsen
2M ago
DYN
Dyne Therapeutics price target lowered to $33 from $34 at Evercore ISI
Premium
The Fly
Dyne Therapeutics price target lowered to $33 from $34 at Evercore ISI
2M ago
DYN
Biogen CELIA topline readout in Alzheimer’s ‘historic,’ says H.C. Wainwright
PremiumThe Fly
Biogen CELIA topline readout in Alzheimer’s ‘historic,’ says H.C. Wainwright
2M ago
DYN
ALEC
Dyne Therapeutics price target raised to $24 from $23 at Bernstein
PremiumThe Fly
Dyne Therapeutics price target raised to $24 from $23 at Bernstein
2M ago
DYN
Trump Trade: Trump to suspend tariff-rate quotas on beef imports
PremiumThe Fly
Trump Trade: Trump to suspend tariff-rate quotas on beef imports
2M ago
AZN
BMY
Trump Trade: U.S. plans AI security order without required model tests
PremiumThe Fly
Trump Trade: U.S. plans AI security order without required model tests
2M ago
DYN
RNA
Trump approves plan to fire FDA head Marty Makary, CBS reports
PremiumThe FlyTrump approves plan to fire FDA head Marty Makary, CBS reports
2M ago
DYN
RNA
Dyne Therapeutics reports Q1 EPS (73c), consensus (78c)
Premium
The Fly
Dyne Therapeutics reports Q1 EPS (73c), consensus (78c)
2M ago
DYN
Dyne Therapeutics: De-Risked DMD Opportunity, Pivotal DM1 Readout, and Emerging M&A Appeal Support Buy Rating
Premium
Ratings
Dyne Therapeutics: De-Risked DMD Opportunity, Pivotal DM1 Readout, and Emerging M&A Appeal Support Buy Rating
3M ago
DYN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >